Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...
Imdelltra improved overall survival in SCLC patients compared to chemotherapy, regardless of CFIs or prior anti-PD-(L)1 therapy. The DeLLphi-304 trial showed significant OS benefits with Imdelltra, ...
Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. HealthDay News — For patients with extensive-stage small cell ...
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody ...
Among 854 patients analyzed, durvalumab was initiated at a median of 5.6 weeks after CCRT (IQR, 4.0-8.3 weeks). When not considering the timing of durvalumab, patients who received durvalumab had ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results